The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | ESMO Clinical Practice Guidelines: beyond EGFR and ALK
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses current indications of precision therapeutics in advanced oncogene-addicted non-small cell lung cancer (NSCLC) beyond EGFR and ALK targeting, highlighting updated ESMO Clinical Practice Guidelines as directing change in oncogene-addicted NSCLC including ROS1, BRAFV600E, RET and NTRK, Exon20, MET 14 skipping and KRASG12C alterations. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
